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ABSTRACT
Rationale Studies suggest that increased breastfeeding
rates can provide substantial ﬁnancial savings, but the
scale of such savings in the UK is not known.
Objective To calculate potential cost savings
attributable to increases in breastfeeding rates from the
National Health Service perspective.
Design and settings Cost savings focussed on where
evidence of health beneﬁt is strongest: reductions in
gastrointestinal and lower respiratory tract infections,
acute otitis media in infants, necrotising enterocolitis in
preterm babies and breast cancer (BC) in women.
Savings were estimated using a seven-step framework in
which an incidence-based disease model determined the
number of cases that could have been avoided if
breastfeeding rates were increased. Point estimates of
cost savings were subject to a deterministic sensitivity
analysis.
Results Treating the four acute diseases in children
costs the UK at least £89 million annually. The 2009–
2010 value of lifetime costs of treating maternal BC is
estimated at £959 million. Supporting mothers who are
exclusively breast feeding at 1 week to continue breast
feeding until 4 months can be expected to reduce the
incidence of three childhood infectious diseases and save
at least £11 million annually. Doubling the proportion of
mothers currently breast feeding for 7–18 months in
their lifetime is likely to reduce the incidence of maternal
BC and save at least £31 million at 2009–2010 value.
Conclusions The economic impact of low
breastfeeding rates is substantial. Investing in services
that support women who want to breast feed for longer
is potentially cost saving.
INTRODUCTION
The prevalence of breast feeding (referred to, here-
after, as ‘breastfeeding rates’) from initiation to
6 months post birth, has been very low in many
Western countries for years.1 There is good quality
evidence (see our systematic review2) showing the
negative impact of using substitutes for breast
feeding on ﬁve diseases in children and mothers;
gastrointestinal (GI) infection, lower respiratory
tract infection (LRTI) and acute otitis media
(AOM) in infants; necrotising enterocolitis (NEC)
in preterm babies and breast cancer (BC) in
mothers. Other conditions including cognitive out-
comes, early years obesity, Sudden Infant Death
Syndrome and markers of longer-term cardiovascu-
lar disease have been associated with the use of sub-
stitutes for breast feeding, but the evidence
available is not in a form appropriate for robust
economic analysis.2
The economic impact of infant feeding is exten-
sive and multifaceted.3 Low rates of breast feeding
impact on costs borne by the health service and
families, through disease and its treatment as well
as expenditure on breast milk substitutes. It has
also been argued that women who breast feed
make a substantive, direct and positive contribution
to the national economy through their supply of
breast milk.4 Previous studies show that increasing
breastfeeding rates could result in substantial cost
savings per year, for example, US$3.37 billion
(in 2007) in the USA (of which US$2.2 billion is
direct medical costs and US$1.17 billion is indirect
costs to include time missed from work and per-
sonal expenses excluding the cost of deaths),5 $A9
million in Australia (in or before 1997)6 and €50
million in The Netherlands (in or before 2007).7
The above ﬁgures are not like-for-like comparisons
due to variation in methods to estimate such
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What is already known on this topic:
▸ Low rates of breast feeding are associated with
increased mortality and morbidity among
infants and mothers.
▸ In the UK and many other high-income
countries, breastfeeding rates are low.
▸ Previous studies reported from countries similar
to the UK indicate that increasing breastfeeding
rates reduces healthcare costs by improving
mother and child health.
What this study adds
▸ Use of breast milk substitutes is associated
with a raised risk of four childhood illnesses
and maternal breast cancer; breast feeding
reduces the related National Health Services
treatment costs.
▸ Supporting mothers who are exclusively breast
feeding 1 week after the birth to continue
breast feeding until 4 months could save at
least £11 million annually, by reducing three
childhood illnesses.
▸ Doubling the proportion of mothers breast
feeding for 7–18 months of their lifetime could
save £31 million at present value, by reducing
maternal breast cancer and increasing both
quantity and quality of life.
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savings. Nevertheless, the evidence from industrialised countries
suggests that increasing breastfeeding rates could be a cost-saving
policy. Interpreting these estimates in a UK context, neverthe-
less, requires consideration of British breastfeeding rates, treat-
ment regimens and healthcare-seeking behaviour.
The number of women starting to breast feed in the UK has
risen sharply over the past 20 years, from 62% in 1990 to 81%
in 2010.1 Despite this increase, rates of breast feeding duration
and exclusivity have remained low (in 2010, 55% were breast
feeding at 6 weeks, 23% exclusively (48% and 21%, respect-
ively, in 20058)), and most women who start to breast feed stop
before they would like to as a result of problems.1 9 This has
encouraged policy makers to set targets and offer ﬁnancial
support to UK health services to implement the Unicef UK Baby
Friendly Initiative and other strategies.
The purpose of this paper is to calculate potential cost savings
to the National Health Service (NHS) attributable to increases in
breastfeeding rates in the UK through preventing the ﬁve diseases
for which evidence of health beneﬁt is strongest. It is expected
that such information will be useful in planning, commissioning
and policy decisions related to breastfeeding support services.
METHODS
The methods of this economic analysis have been described in
detail elsewhere2 and are summarised brieﬂy below.
Identifying priority diseases
The ﬁve priority diseases—four acute diseases in infants and BC
in women—were identiﬁed through an extensive systematic
process that examined high-quality systematic reviews and large,
high-quality UK studies.2 Only reviews and studies that met
quality criteria including adequate measures of exposure to
breast feeding, formula feeding and weaning, and where data
existed to allow economic analysis, were included.
Perspective
The perspective of the economic analysis is the NHS in the UK.
We did not include any costs associated with not breast feeding
that fall on individuals, households and/or any other sectors.
Data on treatment costs and potential cost savings are presented
in 2009–2010 prices.
Time horizon
For three acute conditions (GI, LRTI and AOM), analysis was
limited to the ﬁrst year of life, whereas maternal BC estimates
took a lifetime perspective, and analysis of NEC focussed on
the baby’s stay in a neonatal unit. Where the time horizon was
longer than a year (ie, maternal BC), a discount rate of 3.5%
was used.10
Economic modelling
Building on methods employed in previous studies,3 5 6 a seven-
step framework was developed (see web appendix ﬁgure 1).
First, a ‘base case’, reﬂecting current levels of breast feeding in
the UK, and alternative policy scenarios for each priority
outcome were deﬁned and used to assess the impact of achiev-
ing potential policy targets. All alternative scenarios were based
on breastfeeding rates in the UK. Noting that 90% of women in
the UK who stop breast feeding before 6 weeks do so before
they wish to,8 we assumed that women who initiated breast
feeding could breast feed for considerably longer than at present
with appropriate care and support.11 This facilitated the use of
varied deﬁnitions of breast feeding and the time horizon over
which costs and beneﬁts would accrue. Table 1 shows these
scenarios. For example, scenario A1 envisaged an increase in the
exclusive breast feeding rate at 4 months from 7% (observed in
2005) to 21% (observed at 6 weeks in 2005). This assumes a
policy in which mothers who are breast feeding at 6 weeks are
given appropriate care and support enabling them to breast feed
for at least 4 months.
Next, the reference population was selected as: children born
in the year 2009 for child diseases and a cohort of ‘ﬁrst-time’
(to be meaningful for future policy change) mothers in 2009.
Then, the reference population was divided into two feeding
groups for each policy scenario: breast fed/breast feeding and
non-breast fed/breast feeding, using rates derived from the
Table 1 Policy scenarios developed to model costs and potential savings
Definition of breast feeding and
rate used (base case)* Alternative policy scenarios modelled
Gastrointestinal illnesses
Lower Respiratory tract
infections
Acute otitis media
Scenario A0: current rate (base
case) for ‘exclusive’ breast feeding
rate at 4 months (7%)
Scenario A1: increase from 7% to
21% at 4 months, (21% refers to
the rate currently observed at
6 weeks)
Scenario A2: increase from 7% to
45% at 4 months, 45% refers to
the rate currently observed at
1 week
Scenario A3: increase from 7%
to 65% at 4 months, 65%
refers to the rate currently
observed at birth
Scenario B0: current rate (base
case) for ‘exclusive’ breast feeding
rate at 6 months (0.5%)
Scenario B1: increase from 0.5%
to 7%, (7% refers to the rate
currently observed at 4 months)
Scenario C0: current rate (base
case) for ‘any breast feeding’ rate
at 6 months (25%)
Scenario C1: increase from 25%
to 48%, (48% refers to the rate
currently observed at 6 weeks)
Necrotising enterocolitis Scenario D0: current rate (base
case): Any breast milk feeding rate
at discharge from neonatal unit
neonatal units (35%)
Scenario D1: increase from 35%
to a hypothetical 50%
Scenario D2: increase from 35% to
a hypothetical 75%
Scenario D3: increase from
35% to a hypothetical 100%
Maternal breast cancer Scenario E0: current rates (base
case): 32% parous women never
breast feeding, 36% breast feeding
for ≤6 months, 16% breast
feeding for 7–18 months, 16%
breast feeding for 18+ months
Scenario E1: Increase rate of
breast feeding for ≤6 months to
52%, 16% never, 52%
≤6 months; 16% 7–18 months,
16% 18+ months
Scenario E2: Increase rate of
breast feeding for ≤18 months to
32%, 16% never, 36%
≤6 months 32%, 7–18 months,
16% 18+ months
Scenario E3: Increase rate of
breast feeding for 18+ months
to 32%, 16% never, 36%
≤6 months, 16% 7–18 months,
32% 18+ months
*Source for base case breastfeeding figures: A0-C0 (IFS 20058); D0 (MOSAIC cohort19); E0 (Million Women Study12). Note that at the time of this study, 2010 IFS data1 on breastfeeding
rates were not available. Hence, the use of 2005 IFS data for A0-C0.
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Infant Feeding Survey for child outcomes8 and estimates of life-
time breastfeeding duration derived for BC.12 The differential
disease incidence was obtained using the formula: x=s/(br+1
−b), where x=disease incidence in a non-breastfeeding group,
s=overall incidence of the disease in question, b=current breast-
feeding rate; r=risk ratio in favour of breast feeding, and xr=in-
cidence of the condition in a breastfeeding group.5 The risk
ratios (or ORs where risk ratios were not available) were
abstracted (or calculated) from the primary source, using the
most appropriate deﬁnition of infant feeding for that particular
disease (eg, the time-dependent nature of the exposure and the
disease) and were adjusted for confounders including sociocul-
tural factors. The values of these ratios are given in table 2.
The estimated incidence of care episodes was then multiplied
by the unit cost of a care episode (eg, hospitalisation). For mater-
nal BC, a cohort of 100 000 women was followed-up over their
lifetime, using a simple three-state Markov process (cancer, no
cancer, death), to estimate treatment costs. The relevant care epi-
sodes and unit costs used in the model are provided in table 2.
Total treatment costs for primary and secondary care were
estimated using the relevant UK population for each priority
outcome (eg, 788 486 infants in the case of GI) and savings
compared with the ‘base case’ calculated. In the case of BC, the
incremental beneﬁt that combines a value of £20 000 per
quality-adjusted life year (QALY) gained with treatment costs
was estimated. Lifetime costs and QALYs were discounted prior
to averaging. Life years were adjusted by a utility value of
0.71.13 Findings present the potential savings to the NHS that
might result from increased rates of breast feeding.
Finally, deterministic sensitivity analyses assessed the impact
of uncertainties in key parameters on the predicted cost savings;
disease incidence, ORs, unit costs of treating a care episode or
disease, discount rate and utility values. Values of parameters
were changed one at a time, using the ranges set out in table 2,
to identify the impact on costs and potential savings. Life-years
were adjusted by a utility value of 0.80 and 0.6713 in the sensi-
tivity analysis.
RESULTS
Current treatment costs
The NHS cost of treating three childhood diseases (GI, LRTI,
AOM) was calculated as £75.5 million per year; the cost of
treating NEC in preterm babies was calculated as £13.5 million
per year and the lifetime costs of treating BC in parous women
was calculated as £960 million at present value (table 3).
Potential cost savings
Increasing the proportion of women breast feeding exclusively
for 4 months (7%) to 21% (Policy A1) would reduce hospital
cost associated with GI by approximately £1.2 million per
annum. Increasing the rate further to 45% (Policy A2) or 65%
(Policy A3), would save £3.2 million or £5 m per annum,
respectively. The inclusion of primary care costs would provide
total potential savings associated with this condition of £1.34–
£5.54 million per annum.
Around £2 million per year could be saved in LRTI hospital-
isation costs and £0.3 million per annum in general practitioner
consultation costs by increasing the exclusive breast feeding rate
at 4 months (7%) to 21% (Policy A1) (table 3). Potential cost
savings from avoiding the need to treat AOM in primary care is
estimated to be between £0.28 and £1.16 million, depending on
whether the exclusive breast feeding rates at 6 months increases
from the current 7% to 21% (Policy A1) or 65% (Policy A3).
£2.3 million per year could be saved if the proportion of
babies fed any breast milk (mother’s own or donor milk) until
discharge from neonatal units were to increase from 35% to
50% (table 3). These ﬁgures suggest that the cost of each
Table 2 Key disease parameters and values used to model breastfeeding scenarios**
Outcome Odds ratios in favour of breast feeding Incidence Unit costs (2009/2010 prices)
Gastrointestinal
illnesses
Exclusive breast feeding: Hospitalisation: 0.39 (0.18–
0.85)20 GP visits: 0.28 (0.11–0.69)21Any breast
feeding: Hospitalisation: 0.52 (0.30–0.87)20 GP visits:
0.36 (0.18–0.74)21
Hospital admissions: 17.2/1000
live births*
Primary care consultations: 4682/
100 000 infants <1 year†
Hospital admissions‡: Baseline: £989 per admitted
child Lower quartile: £586 Upper quartile:
£1206Primary care consultation22: Baseline: £36 per
GP consultation Upper end cost: £53
Lower respiratory
tract infection
Exclusive breast feeding: Hospitalisation: 0.70 (0.49–
0.98)20 GP visits: 0.69 (0.47–1.0)23Any breast
feeding: Hospitalisation: 0.67 (0.52–0.88)20 GP visits:
0.65 (0.43–0.96)24
Hospital admissions: 59.1/1000
live births*
Primary care consultations:
23 433/100 000 infants <1 year†
Hospital admissions‡: Baseline: £1078 per admitted
child Lower quartile: £749 Upper quartile:
£1290Primary care consultation22: Baseline: £36 per
GP consultation Upper end cost: £53
Acute otitis media Exclusive breast feeding: GP visits: 0.50 (0.37–
0.70)25Any breast feeding: GP visits: 0.40 (0.21–
0.76)24
Primary care consultations: 136/
100 000 infants <1 year†
Primary care consultation22: Baseline: £36 per GP
consultation Upper end cost: £53
NEC Any breast milk: 0.19 (0.05–0.73)26 NEC cases27: 1/100 neonatal
admissions Surgical NEC: 31%
Medical NEC: 69% Average length
of stay: 26.7 days§
Surgery‡: Baseline: £1450 per episode Lower
quartile: £689 Upper quartile: £1802 Neonatal unit
stay‡: Baseline: £618 per bed-day Lower quartile:
£509 Upper quartile: £712
Maternal breast
cancer
Ever breast feeding vs never breast feeding: 0.96
(0.92–0.99)28 Breast feeding for <6 months vs never:
0.98 (0.95–1.01)28 Breast feeding for 7–18 months vs
never: 0.94 (0.91–0.97)28 Breast feeding for 18+
months vs never: 0.89 (0.84–0.94)28
Breast cancer cases: Lifetime
incidence of 12 500/100 000
population (ie, a lifetime risk of
one in eight)¶
Breast cancer average: Baseline: £11 726 per
case29 Upper end cost: £16 26030
*Infant Feeding Profiles 2002/2003–2009/2010. Beta Test V.7 September 2011 from Department of Health.
†Data made available by the Royal College of GPs Research and Surveillance Weekly Returns Service for 2010.
‡Estimated by research team based on the NHS Reference Costs 2009–2010. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/
DH_123459
§Hospital Episode Statistics 2009–2010: http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=192
¶Breast cancer UK incidence statistics. Cancer Research UK: http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/
**Details of each parameter value can be found in the Appendix to the main report, pp.86–113 available from http://www.unicef.org.uk/Documents/Baby_Friendly/Research/appendices_
preventing_disease_saving_resources.pdf
NEC, necrotising enterocolitis; NHS, National Health Service; GP, general practitioner.
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Table 3 Estimated total costs of treating five identified diseases and potential savings/benefits associated with increased breastfeeding rates in the UK (£, million, 2009–2010 prices)
Gastrointestinal
Lower respiratory tract
infection Acute otitis media
Necrotising
enterocolitis (NEC) Maternal breast cancer (BC)
H p Values Total H p Values Total p Values Total- acute diseases Treatment costs Treatment costs Value health gains* Total
Current treatment costs 13.42 1.33 14.75 50.25 6.65 56.90 3.85 75.5 13.54 959.50 NA 959.50
Savings with
Policy A1 1.20 0.14 1.34 2.16 0.30 2.46 0.28 4.08
Policy A2 3.25 0.38 3.63 5.85 0.80 6.65 0.76 11.04
Policy A3 4.96 0.58 5.54 8.93 1.22 10.25 1.16 16.95
Policy B1 0.56 0.07 0.63 1.00 0.14 1.14 0.13 1.9
Policy C1 1.68 0.23 1.91 4.16 0.59 4.75 0.62 7.28
Policy D1 2.30
Policy D2 6.12
Policy D3 9.95
Policy E1 15.34 7.42 22.76
Policy E2 21.17 10.25 31.42
Policy E3 27.80 13.46 41.26
Total savings from mid-level policy scenario (Policy A2)—acute diseases 11.04
Total savings from mid-level policy scenario (Policy D2)—NEC 6.12
Total savings from mid-level policy scenario (Policy E2)—BC (without value of health gains) 21.17
Total benefits from mid-level policy scenario (Policy E2)—BC (with value of health gains) 31.42
The italics face is used to differentiate table 3 from table 4. One provides ‘total’, the other provides ‘average’ figures. The bold face highlight policies that are recommended as realistic targets in the discussion section.
*Monetary value of health (QALY) gains @ £20 000/QALY;
NA, Not applicable.
H, hospitalisation costs; P, primary care costs.
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neonatal unit admission could be reduced, on average, by at
least £30.
Over £15 million, for a total of 313 817 ﬁrst-time mothers
(the annual cohort in 2009), could be saved in treatment costs
for BC over their lifetime, if half the women who currently do
not breast feed were enabled to breast feed for up to 6 months
during their lifetime (table 3). If the proportion of those ‘never
breast feeding’ was halved, and 32% of women were enabled to
breast feed for a lifetime total of 7–18 months, the net present
value of predicted savings from BC would be over £21 million
over the lifetime of 313 817 ﬁrst-time mothers.
QALY gain
A total of 371 QALYs would also be gained from the reduction
in incidence of BC across the lifetime of 313 817 ﬁrst-time
mothers, if half the number of those not breast feeding currently
were supported to breast feed for up to 6 months in their life-
time. Given a willingness to pay £20 000 per QALY as recom-
mended by the National Institute for Health and Care
Excellence, the net present value of these gains, when combined
with savings from treatment costs, are £23 million, £31 million
and £41 million, respectively, for the three policy scenarios.
Average cost savings
For comparative purposes, these results are also presented as
average costs in table 4. For example, GI in the UK costs the
NHS a total of £17 per infant per year, but potential savings if
exclusive breast feeding increased from 7% to 21% at 4 months
could be £0.92 per infant per year. The potential savings from
NEC could be £77 per neonatal admission per year if the
current rate of breast milk feeding in the neonatal units were to
increase to 75% at discharge.
Sensitivity analysis
Table 5 presents results from the sensitivity analysis showing
sensitivity. The results were most sensitive to the value of ORs
used. For example, the lowest estimate of GI-related cost savings
under policy scenario A1 (£0.34 million) was the result of using
a higher value of OR than the baseline OR (hence less effective).
The use of the lower value of the OR (rather than the baseline
OR) yielded the highest estimate of GI-related savings under
policy scenario A1 (£1.78 million).
DISCUSSION
Main ﬁndings
Supporting mothers who are exclusively breast feeding at
1 week to continue breast feeding until 4 months could save at
least £11 million per year by reducing the incidence of three
acute infections in children. Additionally, increasing the current
rate of breast milk feeding in the neonatal units from 35% to
75% could save £6.12 million per year in treatment costs by
reducing the incidence of NEC. If the proportion of mothers
currently breast feeding for 7–18 months in their lifetime were
to double, a net present value of £21 million savings could be
realised by reducing the incidence of BC over the lifetime of
each annual cohort of ﬁrst-time mothers (plus a further £10
Table 5 Selected results from the sensitivity analyses for policies A1, D1 and E1 (£, million, 2009–2010 prices)
Gastrointestinal illnesses Lower respiratory tract infection Acute otitis media Necrotising enterocolitis Maternal breast cancer
Mean estimate 1.20 2.16 0.28 2.30 22.8
Lowest estimate 0.34 0.44 0.17 0.61 6.00
Highest estimate 1.78 4.50 0.35 2.90 40.0
Cost savings figures are for low-level policy scenario (ie, A1s—E1s) and include only hospitalisation costs for gastrointestinal, lower respiratory tract illnesses and acute otitis media and
treatment costs for necrotising enterocolitis and maternal breast cancer. This sensitivity analysis relates to estimates provided in table 3.
Table 4 Estimated average costs per individual of treating identified diseases and potential cost savings associated with increased
breastfeeding rates in the UK (£, 2009–2010 prices)
Gastrointestinal
illnesses*
Lower respiratory tract
infection*
Acute otitis
media*
Necrotising
enterocolitis†
Maternal breast
cancer‡
Current treatment costs 17.02 75.52 4.88 171.13 3057.51
Savings with:
Policy A1 0.92 3.12 0.35
Policy A2 2.49 8.48 0.96
Policy A3 3.81 12.94 1.47
Policy B1 0.43 1.45 0.16
Policy C1 1.52 6.05 0.79
Policy D1 29.02
Policy D2 77.39
Policy D3 125.75
Policy E1 48.88
Policy E2 67.46
Policy E3 88.59
*Cost per infant.
†Cost per neonatal admission.
‡Cost per primiparous woman.
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million value attributed to QALY gains). These equated to £14
per infant in the ﬁrst year of life, £77 per neonatal admission
and £100 per ﬁrst-time mother, respectively.
Strengths and weaknesses
This is the ﬁrst study to quantify, nationally, the burden of
illness associated with the low breastfeeding rates in the UK and
potential gains to the NHS (from reduced illness, saved costs
and increased quality of life) achievable through increased breast
feeding. We made assumptions about a realistic increase in
breastfeeding rates, but consider these achievable given that
80% of Norwegian mothers,14 68% of Swedish mothers15 and
60% of Australian mothers16 breast feed at 6 months. In fact,
the target rates we have applied to estimate cost savings are
lower than those seen in other European countries. While a
number of alternative scenarios are presented for evaluation, the
mid-level scenarios (Policies A2, D2 and E2) could serve as real-
istic policy targets for interventions.
Comparison with other studies
Our study adds to the global empirical database on the scale of
potential cost savings achievable through increasing breastfeed-
ing rates. In Italy, the difference in treatment costs between
‘fully’ breast fed (exclusively or predominantly for 3 months)
and ‘partially’ breast fed (complementary feeding or no breast
feeding) children was estimated at €160 per infant per year.17
Increasing the exclusive breastfeeding rate at 6 months to 90%
was estimated to save US$3.37 billion per year in treatment
costs in the USA5 and, assuming a 100% breastfeeding rate,
€250 per newborn per year in the Netherlands.7 Achieving an
exclusive breastfeeding rate of 80% at 3 months was estimated
to save SA$9 million per year.6
By contrast, our estimates were based upon relatively small
increments in the prevalence of breast feeding. We took account
of rates achieved in other European countries14 15 as well as the
encouraging trends observed in the UK over the past 25
years.1 18 Greater economic gains would be made were rates to
increase further. Focussing purely on the ﬁve diseases associated
with the strongest evidence base increases the robustness of
results, but also indicates that the calculated savings may be
underestimates.
Implications
It is very important to note that achieving the savings we
describe does not depend upon persuading more women to
breast feed after the birth. Rather it envisages that those women
who have chosen to breast feed will receive better early support
through investment in proactive, accessible, high-quality ser-
vices. This is very important because national statistics indicate
that 80% of women who stop breast feeding in the early weeks
would have liked to have breast fed for longer.1 Our study
should reassure policymakers, service planners and commis-
sioners that a rapid return on investment is realistic and feasible,
supported by cost savings that can be realised in the ﬁrst year of
infants’ lives.
Future research
High-quality evaluations of the effectiveness and cost effective-
ness of interventions that support women to breast feed longer
are now needed. Our ﬁndings can contribute to these studies
through robust estimates of both robust short-term and long-
term effects.
CONCLUSION
Increasing the current breastfeeding rates is likely to generate
substantial cost savings to the NHS in the UK; the actual
amounts saved will depend on the extent of the increase and
the effectiveness of interventions. While the cost of these inter-
ventions must be considered, the potential savings indicate that
substantial further investment has a strong economic case.
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